Skip to main content

08-09-2018 | Sitagliptin | Article

Adverse Drug Events Associated with sitagliptin Versus canagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Comparison Through a Meta-Analysis

Journal: Diabetes Therapy

Authors: Pravesh Kumar Bundhun, Feng Huang

Publisher: Springer Healthcare



In this meta-analysis, we aimed to systematically compare the adverse drug events associated with sitagliptin (100 mg) versus canagliflozin 100 or 300 mg in patients who were treated for type 2 diabetes mellitus (T2DM).


Online databases were searched for relevant studies comparing sitagliptin (100 mg) versus canagliflozin. Adverse drug events were considered as the clinical endpoints. The analysis was carried out by RevMan software whereby risk ratios (RR) and 95% confidence intervals (CI) were generated.


Five studies with a total number of 2322 patients were included. When sitagliptin (100 mg) was compared with canagliflozin (100 mg), the endpoints of any adverse events, adverse events leading to drug discontinuation, serious adverse events, urinary tract infections, hypoglycemia, and adverse events related to hypovolemia were not significantly different: (RR 1.10, 95% CI 1.00–1.21; P = 0.05), (RR 1.20, 95% CI 0.67–2.16; P = 0.54), (RR 0.90, 95% CI 0.49–1.66; P = 0.73), (RR 1.26, 95% CI 0.77–2.08; P = 0.36), (RR 1.01, 95% CI 0.30–3.43; P = 0.99), and (RR 1.76, 95% CI 0.52–5.94; P = 0.36), respectively. However, canagliflozin was associated with increased genital mycotic infection (RR 4.32, 95% CI 2.11–8.83; P = 0.0001). When genital mycotic infections associated with sitagliptin versus canagliflozin were compared in male and female patients separately, the risk was still significantly higher with canagliflozin: (RR 7.00, 95% CI 2.44–20.06; P = 0.003) and (RR 4.02, 95% CI 2.22–7.27; P = 0.00001), respectively. The same results were obtained when sitagliptin (100 mg) was compared to canagliflozin 300 mg.


Canagliflozin was associated with a significantly higher risk of genital mycotic infections when compared to sitagliptin. However, the other adverse drug events were similarly manifested when sitagliptin 100 mg was compared to either canagliflozin 100 or 300 mg.
Hermayer KL, Dake A. Newer oral and noninsulin therapies to treat type 2 diabetes mellitus. Cleve Clin J Med. 2016;83(5 Suppl 1):S18–26.CrossRefPubMed
Tago M, Oyama JI, Sakamoto Y, et al. Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus. Geriatr Gerontol Int. 2018;18(4):631–9.CrossRefPubMed
Cai J, Delahanty LM, Akapame S, Slee A, Traina S. Impact of canagliflozin treatment on health-related quality of life among people with type 2 diabetes mellitus: a pooled analysis of patient-reported outcomes from randomized controlled trials. Patient. 2018;11:341–52.CrossRefPubMedPubMedCentral
Buysman EK, Chow W, Henk HJ, Rupnow MF. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Curr Med Res Opin. 2015;31(1):137–43.CrossRefPubMed
Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23(4):479–86.CrossRefPubMed
Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018;17(4):387–405.CrossRefPubMed
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcareinterventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRefPubMedPubMedCentral
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.CrossRefPubMedPubMedCentral
Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582–92.CrossRefPubMedPubMedCentral
Rodbard HW, Seufert J, Aggarwal N, et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequatelycontrolled on metformin and sitagliptin. Diabetes Obes Metab. 2016;18(8):812–9.CrossRefPubMedPubMedCentral
Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232–8.CrossRefPubMedPubMedCentral
Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508–15.CrossRefPubMedPubMedCentral
Shao YL, Yee KH, Koh SK, et al. Short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting. Singapore Med J. 2017;59:251.CrossRefPubMed
Bailey RA, Vijapurkar U, Meininger GE, Rupnow MF, Blonde L. Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials. Am J Manag Care. 2014;20(13 Suppl):s296–305.PubMed
Bundhun PK, Janoo G, Huang F. Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials. BMC Pharmacol Toxicol. 2017;18(1):19.CrossRefPubMedPubMedCentral
Bundhun PK, Janoo G, Teeluck AR, Huang F. Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2017;18(1):66.CrossRefPubMedPubMedCentral
Dai X, Luo ZC, Zhai L, Zhao WP, Huang F. Adverse drug events associated with low-dose (10 mg) versus high-dose (25 mg) empagliflozinin patients treated for type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetes Ther. 2018;9(2):753–70.PubMedPubMedCentral

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »